Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S.

Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20. Epub 2016 Feb 9.

2.

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R; SAKK and the German CML Study Group.

Ann Hematol. 2015 Dec;94(12):2015-24. doi: 10.1007/s00277-015-2494-9. Epub 2015 Sep 18.

PMID:
26385387
3.

A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia.

Hecht A, Nowak D, Nowak V, Hanfstein B, Büchner T, Spiekermann K, Weiß C, Hofmann WK, Lengfelder E, Nolte F.

Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30363-5. doi: 10.1016/j.leukres.2015.08.010. [Epub ahead of print]

PMID:
26344466
4.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group.

Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.

5.

Response-related predictors of survival in CML.

Hanfstein B, Müller MC, Hochhaus A.

Ann Hematol. 2015 Apr;94 Suppl 2:S227-39. doi: 10.1007/s00277-015-2327-x. Epub 2015 Mar 27. Review.

PMID:
25814089
6.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R.

Leukemia. 2015 May;29(5):1123-32. doi: 10.1038/leu.2015.36. Epub 2015 Feb 13.

PMID:
25676422
7.

Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia.

Hecht A, Nolte F, Nowak D, Nowak V, Reinwald M, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Weiss C, Hofmann WK, Lengfelder E.

Leuk Lymphoma. 2015;56(8):2289-95. doi: 10.3109/10428194.2014.990011. Epub 2015 Jan 21.

PMID:
25426668
8.

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1965-9. doi: 10.1007/s00432-014-1746-8. Epub 2014 Jun 22.

PMID:
24952896
9.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.

10.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.

PMID:
24798484
11.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Ann Hematol. 2014 Jul;93(7):1167-76.

12.

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.

Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayastha D, Woodman RC, Hofmann WK, Hehlmann R, Hochhaus A, Müller MC.

Leukemia. 2014 Jul;28(7):1478-85. doi: 10.1038/leu.2014.6. Epub 2014 Jan 10.

PMID:
24472814
13.

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).

Philipp M, Schwaab J, Dietz CT, Hanfstein B, Kalmanti L, Munjal U, Mossner M, Nowak D, Seifarth W, Hofmann WK, Hochhaus A, Müller MC, Erben P.

J Cancer Res Clin Oncol. 2014 Mar;140(3):411-7. doi: 10.1007/s00432-013-1579-x. Epub 2014 Jan 5.

PMID:
24390277
14.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A.

J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.

PMID:
24297946
15.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Ann Hematol. 2014 Jan;93(1):71-80. doi: 10.1007/s00277-013-1937-4. Epub 2013 Oct 27.

16.

In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival.

Nolte F, Hecht A, Reinwald M, Nowak D, Nowak V, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Hofmann WK, Lengfelder E.

Leuk Res. 2013 Apr;37(4):378-82. doi: 10.1016/j.leukres.2012.11.018. Epub 2012 Dec 31.

PMID:
23287429
17.

High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia.

Hecht A, Nowak D, Nowak V, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Lengfelder E, Hofmann WK, Nolte F.

Ann Hematol. 2013 Apr;92(4):443-9. doi: 10.1007/s00277-012-1648-2. Epub 2012 Dec 19. Erratum in: Ann Hematol. 2014 Aug;93(8):1447.

PMID:
23250622
18.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Ann Hematol. 2013 Jan;92(1):41-52. doi: 10.1007/s00277-012-1597-9. Epub 2012 Oct 23.

19.

SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A, Hütter G, Ogawa S, Kohlmann A, Haferlach C, Schlegelberger B, Braess J, Seifarth W, Fabarius A, Erben P, Saussele S, Müller MC, Reiter A, Buechner T, Weiss C, Hofmann WK, Lengfelder E.

Genes Chromosomes Cancer. 2012 Aug;51(8):756-67. doi: 10.1002/gcc.21961. Epub 2012 Apr 9.

PMID:
22488577
20.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A; SAKK; German CML Study Group.

Leukemia. 2012 Sep;26(9):2096-102. doi: 10.1038/leu.2012.85. Epub 2012 Mar 26.

PMID:
22446502
21.

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.

Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, Hochhaus A, La Rosée P.

J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.

PMID:
22089930
22.

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group.

Blood. 2011 Dec 22;118(26):6760-8. doi: 10.1182/blood-2011-08-373902. Epub 2011 Oct 28.

23.

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.

Hanfstein B, Müller MC, Kreil S, Ernst T, Schenk T, Lorentz C, Schwindel U, Leitner A, Hehlmann R, Hochhaus A.

Haematologica. 2011 Mar;96(3):360-6. doi: 10.3324/haematol.2010.030999. Epub 2010 Dec 6.

24.

KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.

Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kähler G, Kienle P, Post S, Wenz F, Hochhaus A, Hofheinz RD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1032-8. doi: 10.1016/j.ijrobp.2010.06.043. Epub 2010 Oct 13.

PMID:
20947270
25.

Harmonization of molecular monitoring of CML therapy in Europe.

Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A.

Leukemia. 2009 Nov;23(11):1957-63. doi: 10.1038/leu.2009.168. Epub 2009 Aug 27. Review.

PMID:
19710700
26.

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP.

Leukemia. 2009 Sep;23(9):1628-33. doi: 10.1038/leu.2009.156. Epub 2009 Jul 30.

PMID:
19641527
27.

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Ernst T, Hoffmann J, Erben P, Hanfstein B, Leitner A, Hehlmann R, Hochhaus A, Müller MC.

Haematologica. 2008 Sep;93(9):1389-93. doi: 10.3324/haematol.12964. Epub 2008 Jul 4.

28.

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.

Sacha T, Hochhaus A, Hanfstein B, Müller MC, Rudzki Z, Czopek J, Wolska-Smoleń T, Czekalska S, Salamanchuk Z, Jakóbczyk M, Skotnicki AB.

Leuk Res. 2003 Dec;27(12):1163-6.

PMID:
12921956
29.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.

Leukemia. 2002 Nov;16(11):2190-6.

Supplemental Content

Loading ...
Support Center